Patents by Inventor Hideto Kaneshima

Hideto Kaneshima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6093872
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: February 13, 1992
    Date of Patent: July 25, 2000
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph McCrary McCune
  • Patent number: 5645982
    Abstract: The invention provides methods for screening agents for potential anti-viral effects by assessing the ability of the agents to suppress viral replication and/or pathology in thymic cells grown in thymic organ culture in vitro. Also provided are methods to study viral pathology and infectivity.
    Type: Grant
    Filed: August 19, 1993
    Date of Patent: July 8, 1997
    Assignee: SyStemix, Inc.
    Inventors: Mark L. Bonyhadi, Joseph M. McCune, Hideto Kaneshima
  • Patent number: 5633426
    Abstract: Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: May 27, 1997
    Assignee: Systemix, Inc.
    Inventors: Reiko Namikawa, Seishi Kyoizumi, Joseph M. McCune, Hideto Kaneshima
  • Patent number: 5625127
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: April 29, 1997
    Assignee: SyStemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
  • Patent number: 5612018
    Abstract: A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4.sup.+ -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: March 18, 1997
    Assignee: Systemix, Inc.
    Inventors: Mark L. Bonyhadi, Hideto Kaneshima, Joseph M. McCune, Reiko Namikawa, Lishan Su
  • Patent number: 5601975
    Abstract: The invention provides methods for screening agents for potential anti-viral effects by assessing the ability of the agents to suppress viral replication and/or pathology in thymic cells grown in thymic organ culture in vitro. Also provided are methods to study viral pathology and infectivity.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 11, 1997
    Assignee: SyStemix, Inc.
    Inventors: Mark L. Bonyhadi, Joseph M. McCune, Hideto Kaneshima
  • Patent number: 5516977
    Abstract: Immunocompromised hosts comprising xenogeneic fetal lymph node tissue implanted in the ear pinna are provided. The chimeric hosts are prepared by inserting the xenogeneic lymph node tissue into the ear pinna and closing the incision. The tissue is found to be rapidly vascularized and can be productively infected with HIV.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: May 14, 1996
    Assignee: Systemix, Inc.
    Inventors: Brian Ford, Hideto Kaneshima
  • Patent number: 5476997
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: December 19, 1995
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
  • Patent number: 5411749
    Abstract: Human lymphoid tissue is introduced into an immunocompromised host to provide opportunities to investigate the effect of stimuli on the human immune system and obtain information and products from the stimulus. Particularly, methodology is provided for the production of human monoclonal antibodies by introducing lymphoid tissue into an immunocompromised host, stimulating the B-lymphocytes with an appropriate immunogen, harvesting the tissue and immortalizing and/or cloning the B-lymphocytes under conditions to obtain a stable supply of monoclonal antibodies.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: May 2, 1995
    Assignee: Systemix, Inc.
    Inventors: Susan K. Mayo, Reiko Namikawa, Hideto Kaneshima, Joseph M. McCune